{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:26:33Z","timestamp":1793330793956,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-024-55331-6","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T18:24:13Z","timestamp":1735583053000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["AI allows pre-screening of FGFR3 mutational status using routine histology slides of muscle-invasive bladder cancer"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-1175-2976","authenticated-orcid":false,"given":"Pierre-Antoine","family":"Bannier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3061-839X","authenticated-orcid":false,"given":"Charlie","family":"Saillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2857-4861","authenticated-orcid":false,"given":"Philipp","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Touzot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Maussion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Matek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Kl\u00fcmper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Breyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Wirtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danijel","family":"Sikic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Schmitz-Dr\u00e4ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Wullich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arndt","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4740-6900","authenticated-orcid":false,"given":"Sebastian","family":"F\u00f6rsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5418-3349","authenticated-orcid":false,"given":"Markus","family":"Eckstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,30]]},"reference":[{"key":"55331_CR1","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1001\/jama.2020.17598","volume":"324","author":"AT Lenis","year":"2020","unstructured":"Lenis, A. T., Lec, P. M., Chamie, K. & Mshs, M. D. Bladder cancer: a review. JAMA 324, 1980\u20131991 (2020).","journal-title":"JAMA"},{"key":"55331_CR2","first-page":"15","volume":"8","author":"K Saginala","year":"2020","unstructured":"Saginala, K. et al. Epidemiology of bladder cancer. Med. Sci. 8, 15 (2020).","journal-title":"Med. Sci."},{"key":"55331_CR3","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles, T. et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N. Engl. J. Med. 390, 875\u2013888 (2024).","journal-title":"N. Engl. J. Med."},{"key":"55331_CR4","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1016\/S0002-9440(10)64665-2","volume":"158","author":"C Billerey","year":"2001","unstructured":"Billerey, C. et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am. J. Pathol. 158, 1955\u20131959 (2001).","journal-title":"Am. J. Pathol."},{"key":"55331_CR5","doi-asserted-by":"publisher","first-page":"102530","DOI":"10.1016\/j.ctrv.2023.102530","volume":"115","author":"CM Ascione","year":"2023","unstructured":"Ascione, C. M. et al. Role of FGFR3 in bladder cancer: treatment landscape and future challenges. Cancer Treat. Rev. 115, 102530 (2023).","journal-title":"Cancer Treat. Rev."},{"key":"55331_CR6","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1158\/1535-7163.MCT-12-1150","volume":"12","author":"KM Gust","year":"2013","unstructured":"Gust, K. M. et al. Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer. Mol. Cancer Ther. 12, 1245\u20131254 (2013).","journal-title":"Mol. Cancer Ther."},{"key":"55331_CR7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/path.2207","volume":"213","author":"D Tomlinson","year":"2007","unstructured":"Tomlinson, D., Baldo, O., Harnden, P. & Knowles, M. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J. Pathol. 213, 91\u201398 (2007).","journal-title":"J. Pathol."},{"key":"55331_CR8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrc3817","volume":"15","author":"MA Knowles","year":"2015","unstructured":"Knowles, M. A. & Hurst, C. D. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat. Rev. Cancer 15, 25\u201341 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"55331_CR9","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1817323","volume":"381","author":"Y Loriot","year":"2019","unstructured":"Loriot, Y. et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N. Engl. J. Med. 381, 338\u2013348 (2019).","journal-title":"N. Engl. J. Med."},{"key":"55331_CR10","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","volume":"389","author":"Y Loriot","year":"2023","unstructured":"Loriot, Y. et al. Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma. N. Engl. J. Med. 389, 1961\u20131971 (2023).","journal-title":"N. Engl. J. Med."},{"key":"55331_CR11","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.euf.2021.04.007","volume":"8","author":"CML Loeffler","year":"2022","unstructured":"Loeffler, C. M. L. et al. Artificial intelligence\u2013based detection of FGFR3 mutational status directly from routine histology in bladder cancer: a possible preselection for molecular testing? Eur. Urol. Focus 8, 472\u2013479 (2022).","journal-title":"Eur. Urol. Focus"},{"key":"55331_CR12","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1038\/s41591-023-02562-7","volume":"29","author":"CRS Banerji","year":"2023","unstructured":"Banerji, C. R. S., Chakraborti, T., Harbron, C. & MacArthur, B. D. Clinical AI tools must convey predictive uncertainty for each individual patient. Nat. Med. 29, 2996\u20132998 (2023).","journal-title":"Nat. Med."},{"key":"55331_CR13","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.eururo.2020.07.002","volume":"78","author":"BWG van Rhijn","year":"2020","unstructured":"van Rhijn, B. W. G. et al. FGFR3 mutation status and FGFR3 expression in a large bladder cancer cohort treated by radical cystectomy: implications for anti-FGFR3 treatment?\u2020. Eur. Urol. 78, 682\u2013687 (2020).","journal-title":"Eur. Urol."},{"key":"55331_CR14","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/978-1-0716-3291-8_17","volume":"2684","author":"V Bahlinger","year":"2023","unstructured":"Bahlinger, V., Eckstein, M., Hartmann, A. & St\u00f6hr, R. Evaluation of FGFR alteration status in urothelial tumors. Methods Mol. Biol. 2684, 283\u2013291 (2023).","journal-title":"Methods Mol. Biol."},{"key":"55331_CR15","doi-asserted-by":"publisher","first-page":"4805","DOI":"10.1002\/cam4.4044","volume":"10","author":"CS Velmahos","year":"2021","unstructured":"Velmahos, C. S., Badgeley, M. & Lo, Y.-C. Using deep learning to identify bladder cancers with FGFR-activating mutations from histology images. Cancer Med. 10, 4805\u20134813 (2021).","journal-title":"Cancer Med."},{"key":"55331_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01897-6","volume":"22","author":"K Komura","year":"2023","unstructured":"Komura, K. et al. The Impact of FGFR3 alterations on the tumor microenvironment and the efficacy of immune checkpoint inhibitors in bladder cancer. Mol. Cancer 22, 185 (2023).","journal-title":"Mol. Cancer"},{"key":"55331_CR17","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.eururo.2019.06.025","volume":"76","author":"L Wang","year":"2019","unstructured":"Wang, L. et al. Fibroblast growth factor receptor 3 alterations and response to PD-1\/PD-L1 blockade in patients with metastatic urothelial cancer. Eur. Urol. 76, 599\u2013603 (2019).","journal-title":"Eur. Urol."},{"key":"55331_CR18","first-page":"A68","volume":"19","author":"K Tomczak","year":"2015","unstructured":"Tomczak, K., Czerwi\u0144ska, P. & Wiznerowicz, M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp. Oncol. 19, A68\u2013A77 (2015).","journal-title":"Contemp. Oncol."},{"key":"55331_CR19","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1159\/000317055","volume":"77","author":"S Koufou","year":"2010","unstructured":"Koufou, S. et al. Mutational activation of FGFR3 is not involved in the development of prostate cancer. Pathobiol. J. Immunopathol. Mol. Cell. Biol. 77, 249\u2013252 (2010).","journal-title":"Pathobiol. J. Immunopathol. Mol. Cell. Biol."},{"key":"55331_CR20","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1172\/JCI28163","volume":"116","author":"C Hafner","year":"2006","unstructured":"Hafner, C. et al. Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi. J. Clin. Investig. 116, 2201\u20132207 (2006).","journal-title":"J. Clin. Investig."},{"key":"55331_CR21","doi-asserted-by":"publisher","first-page":"7743","DOI":"10.1158\/1078-0432.CCR-05-1045","volume":"11","author":"JMM van Oers","year":"2005","unstructured":"van Oers, J. M. M. et al. A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine. Clin. Cancer Res. 11, 7743\u20137748 (2005).","journal-title":"Clin. Cancer Res."},{"key":"55331_CR22","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1158\/0008-5472.CAN-20-2336","volume":"81","author":"A Wullweber","year":"2021","unstructured":"Wullweber, A. et al. Bladder tumor subtype commitment occurs in carcinoma in situ driven by key signaling pathways including ECM remodeling. Cancer Res. 81, 1552\u20131566 (2021).","journal-title":"Cancer Res."},{"key":"55331_CR23","doi-asserted-by":"publisher","first-page":"10267","DOI":"10.3390\/ijms231810267","volume":"23","author":"SA K\u00f6hler","year":"2022","unstructured":"K\u00f6hler, S. A. et al. Improved bladder tumor RNA isolation from archived tissues using methylene blue for normalization, multiplex RNA hybridization, sequencing and subtyping. Int. J. Mol. Sci. 23, 10267 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"55331_CR24","doi-asserted-by":"publisher","unstructured":"Ronneberger, O. et al. U-Net: convolutional networks for biomedical image segmentation. Medical Image Computing and Computer-Assisted Intervention \u2013 MICCAI 2015. Lecture Notes in Computer Science, vol 9351. https:\/\/doi.org\/10.1007\/978-3-319-24574-4_28 (Springer, Cham, 2015).","DOI":"10.1007\/978-3-319-24574-4_28"},{"key":"55331_CR25","unstructured":"Saillard, C. et al. H-optimus-0. GitHub https:\/\/github.com\/bioptimus\/releases\/tree\/main\/models\/h-optimus\/v0 (2024)."},{"key":"55331_CR26","doi-asserted-by":"publisher","unstructured":"Oquab, M. et al. DINOv2: learning robust visual features without supervision. Preprint at https:\/\/doi.org\/10.48550\/arXiv.2304.07193 (2024).","DOI":"10.48550\/arXiv.2304.07193"},{"key":"55331_CR27","unstructured":"Courtiol, P., Tramel, E. W., Sanselme, M. & Wainrib, G. Classification and disease localization in histopathology using only global labels: a weakly-supervised approach. ArXiv180202212 Cs Stat (2020)."},{"key":"55331_CR28","unstructured":"Lakshminarayanan, B., Pritzel, A. & Blundell, C. Simple and scalable predictive uncertainty estimation using deep ensembles. In Proc. the 31st International Conference on Neural Information Processing Systems, 6405\u20136416 (2017)."},{"key":"55331_CR29","doi-asserted-by":"crossref","unstructured":"Lei J. & Wasserman, L. Distribution-free prediction bands for non-parametric regression. J. R. Stat. Soc. Ser. B Stat. Methodol. https:\/\/academic.oup.com\/jrsssb\/article\/76\/1\/71\/7075937 (2013).","DOI":"10.1111\/rssb.12021"},{"key":"55331_CR30","doi-asserted-by":"publisher","unstructured":"Papadopoulos, H., Proedrou, K., Vovk, V. & Gammerman, A. Inductive confidence machines for regression. In Proc. 13th European Conference on Machine Learning (eds. Elomaa, T., Mannila, H. & Toivonen, H.) 345\u2013356. https:\/\/doi.org\/10.1007\/3-540-36755-1_29 (Springer, 2002).","DOI":"10.1007\/3-540-36755-1_29"},{"key":"55331_CR31","doi-asserted-by":"crossref","unstructured":"Angelopoulos A.N. & Bates, S. Conformal prediction: a gentle introduction. Found. Trends Mach. Learn. 16, 494\u2013591. (2023).","DOI":"10.1561\/2200000101"},{"key":"55331_CR32","doi-asserted-by":"publisher","unstructured":"Bannier, P.-A. & Saillard, C. FGFR3MUT: AI allows pre-screening of FGFR3 mutational status using routine histology slides of muscle-invasive bladder cancer. Zenodo https:\/\/doi.org\/10.5281\/zenodo.13959978 (2024).","DOI":"10.5281\/zenodo.13959978"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-55331-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-55331-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-55331-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T19:04:15Z","timestamp":1735585455000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-55331-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,30]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["55331"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-55331-6","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,30]]},"assertion":[{"value":"17 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Owkin employees own the company\u2019s stocks (P.-A.B., C.S., M.T., P.M., C.M.). B.S-D: consultant for Arquer Ltd, UK, Cepheid, CA, USA, Concile GmbH, Germany, and Nucleix Inc., Israel. B.W.: received speaker\u2019s honoraria from MSD and Janssen\u2010Cilag. N.K.: Personal fees, travel costs, and speaker\u2019s honoraria from Astellas, Novartis, Ipsen, Photocure, MSD, BicycleTX; advisory role for BicycleTX; research funding from BicycleTX. A.H.: Honoraria for lectures for Abbvie, AstraZeneca, Biontech, BMS, Boehringer Ingelheim, Cepheid, Diaceutics, Ipsen, Janssen, Lilly, MSD, Nanostring, Novartis, Roche, 3DHistotech; Consulting\/advisory role for Abbvie, AstraZeneca, Biontech, BMS, Boehringer Ingelheim, Cepheid, Diaceutics, Gilead, Illumina, Ipsen, Janssen, Lilly, MSD, Nanostring, Novartis, Qiagen, QUIP GmbH, Roche, 3DHistotech; research support from AstraZeneca, Biontech, Cepheid, Gilead, Illumina, Janssen, Nanostring, Qiagen, QUIP GmbH, Roche. M.E.: Personal fees, travel costs, and speaker\u2019s honoraria from Eisai, MSD, AstraZeneca, Janssen-Cilag, Cepheid, Roche, Astellas, Diaceutics, Owkin, BMS, BicycleTX; research funding from AstraZeneca, Janssen-Cilag, STRATIFYER, Cepheid, Roche, Gilead, Owkin, QUIP GmbH, BicycleTX; advisory roles for Ferring, Diaceutics, MSD, AstraZeneca, Janssen-Cilag, GenomicHealth, Owkin, BMS, BicycleTX. R.M.W. is the CEO of STRATIFYER. All other authors declare no conflict of interest regarding the present work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10914"}}